Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Taps Investment Firm To Help Fund Phase III Alzheimer’s Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly retains ownership and control over compounds; deal frees resources for development of other pipeline molecules.

You may also be interested in...



Blinding Them With Science: Genentech Tries To Win Shareholders Over

Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked

Blinding Them With Science: Genentech Tries To Win Shareholders Over

Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked

Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets

Sources close to the situation say the merged Pfizer/Wyeth entity will probably maintain ongoing Phase III development programs for both dimebon, the Alzheimer's disease medicine Pfizer in-licensed earlier this year, and bapineuzumab, the antibody being tested by Wyeth and Elan. And the reason has as much to do with the much-bandied "shots on goal" strategy as with efficacy signals exhibited so far by either drug

Related Content

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel